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Protocol
AbstrACt
Introduction It has been argued that tapentadol may 
pharmacologically have lower abuse potential than other 
pharmaceutical opioids currently available. However, there 
has been no comprehensive triangulation of data regarding 
use and harms associated with this formulation. A 
sustained-release formulation (SRF) of tapentadol (Palexia) 
was released in Australia in 2011 and listed for public 
subsidy in 2013. We summarise here the methods of a 
postmarketing study which will measure postintroduction: 
(1) population level availability, (2) extramedical use and 
diversion, (3) attractiveness for extramedical use and (4) 
associated harms, of tapentadol compared against other 
pharmaceutical opioids.
Methods and analysis We evaluated key sources on 
pharmaceutical use and harms in Australia. This review 
indicateddata from four sources that disaggregate 
pharmaceutical opioid formulations and capture tapentadol 
SRF could be triangulated. These data sources comprised: 
(1) national pharmaceutical opioid community sales data 
from 2011 to 2017, (2) national pharmaceutical opioid 
poisonings reported to Poison Information Centres (PICs) 
from 2011 to 2017, (3) number of vendors on online 
marketplaces listing pharmaceutical opioids for sale 
and (4) data on pharmaceutical opioid extramedical use, 
attractiveness and harms from interviews with people who 
regularly inject drugs in Australia.
Ethics and dissemination Ethics approval is not required 
for use of pharmaceutical sales data. Ethics approval has 
been obtained for use of national pharmaceutical opioid 
poisonings reported to PICs (LNR/16/SCHN/44) and for 
use of online marketplace data and interview data from 
people who inject drugs (HC12086). Key findings will be 
published mid-2018 in a peer-reviewed academic journal, 
and presented at various conferences and professional 
meetings.
IntroduCtIon 
In the past two decades, there has been an 
increase in the number of pharmaceutical 
opioids available, and in the prescribing of 
these drugs, in several high-income countries, 
including North America and Australia.1 
Indeed, between 1992 and 2012, the number 
of pharmaceutical opioid dispensing 
episodes increased 15-fold in Australia.2 This 
increase in availability in Australia has been 
accompanied by greater rates of extramed-
ical use, defined as use outside the bounds 
of a doctor's prescription.3 The risk of opioid 
dependence and serious adverse events (eg, 
overdose) associated with extramedical use 
has made addressing this problem a public 
health imperative.4 5 
Opioids differ in the extent to which they 
are likely to be associated with hazardous 
patterns of use due to different potencies 
(ie, weak to strong opioids), pharmacoki-
netic characteristics (eg, rate of metabo-
lism) and propensities for dependence.6 The 
need to reduce extramedical use must also 
be balanced against the need for access to 
opioid therapy for pain. Thus, current public 
health agency strategies to reduce extramed-
ical pharmaceutical opioid use and chronic 
pain prescribing guidelines focus on products 
which have limited or no abuse potential.7 8
Tapentadol is a centrally acting opioid 
analgesic with dual mechanisms of action, 
specifically µ-opioid receptor agonist and 
norepinephrine reuptake inhibition. This 
dual action is thought to result in a lower 
strengths and limitations of this study
 ► This study will comprise the first published compre-
hensive assessment of tapentadol sustained-release 
formulation use, extramedical use, attractiveness for 
extramedical use and associated harms.
 ► The number of data sources is limited relative to 
other postmarketing studies of pharmaceutical opi-
oids as tapentadol is rarely coded separate to other 
pharmaceutical opioids in administrative data.
 ► However, this study will overview a wealth of data 
from the general population and a group at high 
risk for extramedical use, both of which are key to 
examine when quantifying various impacts of phar-
maceutical opioids.
 ► These findings will have relevance to other countries 
where tapentadol has recently been introduced or 
where it may be introduced in the future.
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dose required to produce a given level of analgesia.9 Clin-
ical trials suggest that tapentadol provides equivalent or 
superior levels of pain relief for acute and chronic pain 
similar to oxycodone and morphine, with greater gastro-
intestinal tolerability in terms of reduced rates of nausea, 
vomiting and constipation.10–13
A recent review by the World Health Organization’s 
Expert Committee on Drug Dependence11 concluded 
that potential for abuse for tapentadol may be similar to 
or slightly lower than other opioids such as hydromor-
phone, oxycodone, morphine and tramadol. However, 
they note that these conclusions are tentative given a 
lack of data regarding tapentadol ‘abuse, dependence, 
diversion, recreational use or poison control’, noting that 
tapentadol generally does not feature in drug use surveys 
or surveillance reports. The few studies which have been 
conducted are based on US samples, typically evaluating 
outcomes in using treatment-seeking populations14 or 
assessing internet discussions15 16 and prescribing data17 
todetermine extramedical use. Early indications of rates 
of abuse and diversion from these studies show equiva-
lence to hydromorphone and lower than oxycodone and 
most other strong opioids.14 18
The immediate release formulation of tapentadol is 
registered in Australia for moderate to severe pain, while 
the sustained release formulation is registered for severe 
pain which requires constant opioid treatment and for 
which no other opioid other treatments are adequate.19 
Although a sustained-release formulation of tapentadol 
(SRF; Palexia SR) was released in Australia in 2011, 
and listed for subsidy on the Pharmaceutical Benefits 
Scheme in November 2013,20 no research into rates into 
dispensing, extramedical use and associated harms of the 
tapentadol SRF has been undertaken in Australia. Given 
the broader context of rising rates of pharmaceutical 
opioid use and harms (including overdose), monitoring 
new formulations in terms of population level pharma-
ceutical opioid use, and extramedical use among high-
risk populations (eg, those reporting extramedical use of 
other pharmaceutical use), is critical.
This paper outlines the design for a national post-
marketing study of use, extramedical use and harms 
associated with introduction of the tapentadol SRF 
in Australia. This study will integrate population and 
sentinel high-risk population data, including national 
pharmaceutical opioid sales data, interviews with people 
who inject drugs, and national opioid-related poisoning 
event data.
MEthods And AnAlysIs
study aims
The overarching aim of this study is to identify extra-
medical use and diversion of tapentadol SRF, attractive-
ness for extramedical use and associated levels of harms 
compared with these indicators for other pharmaceutical 
opioid use. The specific questions we aim to answer are 
as follows:
1. What is the population level availability of the tapen-
tadol SRF in Australia relative to other pharmaceuti-
cal opioids?
2. Are there indications of extramedical use of the 
tapentadol SRF (specifically, non-prescribed use, use 
via routes that require tampering), and how does this 
compare to other pharmaceutical opioids?
3. What is the relative attractiveness for extramedical use 
(eg, street price) of the tapentadol SRF, and how does 
this compare to other pharmaceutical opioids?
4. Are there indications of associated harm with the 
tapentadol SRF (specifically, self-reported non-fa-
tal overdose, as well as intentional poisoning, extra-
medical use and abuse as identified through Poison 
Information Centre (PIC) data), and how does this 
compare to other pharmaceutical opioids?
study design and setting
This study is being conducted in Australia. There are 
three main components of this study: analyses of existing 
routine data sources (2011–2017); analyses of data from 
monitoring online drug marketplaces (2013–2017) and 
analyses of cross-sectional data collected from a high-
risk sentinel group (people who inject drugs) partici-
pating in the Illicit Drug Reporting System (IDRS) in 
2016.
Most indicator data sets in Australia do not routinely 
separate tapentadol from other pharmaceutical opioids, 
precluding any comparison of population-level availability 
(see online supplementary appendix 1). Five data sources 
were identified which could provide data specific to phar-
maceutical opioid brand, thus allowing analysis of use and 
harms related to tapentadol SRF. Prescription monitoring 
programme data, although theoretically useful, only exist 
in one jurisdiction, where registration is voluntary and 
implementation is not complete or consistent, and util-
isation of this programme irregular. Consequently, four 
data sources were included in this study: pharmaceutical 
opioid sales data; PIC call data; online drug marketplace 
data and interviews with people who inject drugs. Table 1 
outlines the relevant outcome for each data source for 
each research question.
Pharmaceutical opioid sales data
A third-party access request to obtain pharmaceu-
tical sales data in Australia has been approved by IMS 
Health. Requested data include all pharmaceutical opioid 
purchases through pharmaceutical wholesalers and 
manufacturers who sold direct to pharmacies between 
2011 and 2017. Data will reflects community sales only, 
excluding sales to hospitals. However, due to the legal 
requirements for secure storage of pharmaceuticals in 
pharmacies, and monitoring and recording of opioids 
depending on their schedule listing, the number of packs 
sold over a 12-month period closely approximates the 
number used.
All opioids available in Australia that are indicated of 
pain will be included and coded according to the WHO’s 
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Anatomical Therapeutic Classification system (http://
www. whocc. no/ atc_ ddd_ index/) 
Code of A02A ‘opioids’ and A02B ‘other analgesics 
and antipyretics’. This includes, but is not limited to, 
tapentadol (N02AX06), buprenorphine (N02AE01), 
prescription and over-the-counter codeine (N02BA51, 
N02BE51, N02AA59, R05DA04), dextropropoxyphene 
(N02AC04, N02AC54), fentanyl (N02AB03), hydromor-
phone (N02AA03), methadone (N02AC52), morphine 
(N02AA01) and oxycodone (N02AA05, N02AA55). 
Injectable formulations will be excluded, being mainly 
prescribed in hospitals, and formulations of metha-
done and buprenorphine used solely for the treatment 
of opioid dependence are excluded. However, over-
the-counter codeine is captured in this data source. 
IMS Health data will be provided from January 2011 to 
December 2017 aggregated monthly by opioid formula-
tion, brand, strength and geographic unit.
PIC call data
Four PICs in Australia, based in New South Wales, 
Queensland, Victoria and Western Australia, together 
provide nationwide, round-the-clock poisoning advice 
to healthcare professionals and members of the public. 
National data will be extracted regarding number of 
cases of pharmaceutical opioid exposure poisonings 
(including over-the-counter codeine) reported to PICs. 
Specifically, opioid-related calls will only be extracted 
where the exposure type/intent is coded as ‘recreational’, 
so as to identify exposures where pharmaceutical opioids 
were taken for its intoxicating effects.21 Where the inten-
tional exposure subtype is not available or unclear, calls 
regarding opioids will undergo a free-text search for 
markers of extramedical use and abuse (defined here as 
use of a drug in a way or for a purpose outside intended 
medical use, eg, excess quantity, recreational use, use for 
non-approved purposes), then manually reviewed by PIC 
staff and recoded.
Unit-level data collected between January 2011 and 
December 2017 will be extracted. Data fields to be 
extracted include call date, age group, gender, state/
territory, dose, brand, active ingredients and route of 
exposure.
Online drug marketplace data
An existing surveillance system in Australia monitors 
availability and types of substances sold online via the 
darknet.22 23 The darknet is accessible only via The Onion 
Router, software that enables anonymous communica-
tion. Cryptomarkets (markets operating on the darknet) 
have been accessed weekly since 2013 using a dedicated 
user account. Exhaustive snapshots of each accessible 
marketplace are taken, including details of vendor name, 
listing description and, where possible, country of origin. 
For this study, the number of vendors listing illicit phar-
maceutical opioids for sale on cryptomarkets between 
January 2013 and December 2017 will be extracted by 
brand and by month. This data cannot provide any 
Table 1 Summary of the primary outcomes from each data source
Research outcome
Pharmaceutical opioid 
sales data
Interviews with people 
who inject drugs
Online drug 
marketplace data
Poisons Information 
Centre calls
Research question 1: exposure
  Population level 
availability
Research question 2: extramedical use
  Levels of extramedical 
use (diverted)
  Injection
  Snorting
  Chewing
  Perceived availability 
(diverted)
Research question 3: attractiveness
  Attractiveness for 
extramedical use 
(market value)
Research question 4: harms
  Overdose—non-fatal
  Intentional exposure 
(intentional self-
poisoning, misuse 
and abuse)
Fields filled with black indicate outcomes which can be measured using the given data source.
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information about consumers who are buying drugs on 
the cryptomarkets, or any data on the total number of 
sales via these sites. However, it does yield timely and 
sensitive information regarding drug availability online.
IDRS data
The IDRS is a national illicit drug monitoring system, one 
part of which comprises annual interviews with approxi-
mately 900 people who inject drugs interviewed in each 
capital city in Australia. Participants are recruited using 
multiple methods, including advertisements in street 
press, newspapers, treatment agencies, needle and syringe 
programmes and peer referral. To be eligible to partici-
pate, participants need to be at least 17 years of age; have 
injected at least monthly during the 6 months preceding 
interview; and have been a resident for at least 12 months 
in the capital city in which they are interviewed. The 
interview is administered by trained research staff face-
to-face at a time and location convenient to them, and 
participants receive $AUD40 reimbursement.
The core quantitative interview monitors patterns of 
drug use and includes questions on price, purity and 
availability of the main drug types, including pharmaceu-
tical opioids.24 Data will be used from the 2017 interview 
(conducted May-June 2017), which included additional 
items around tapentadol SRF use. These items pertained 
to:
 ► Levels of tapentadol extramedical use: diverted 
Palexia SR, swallowed, injected, smoked, snorted 
(past 6 months use and number of days).
 ► Other opioid use (pharmaceuticals and heroin): swal-
lowed, injected, smoked, snorted (past 6 months use 
and number of days).
 ► Street (diverted) price and perceived availability of 
diverted tapentadol and other opioids.
 ► Attractiveness of tapentadol for use via injection.
 ► Overdose (each opioid).
data analysis
Population-level data
Opioid utilisation (IMS Health) and intentional phar-
maceutical opioid exposure poisonings (PIC) data 
will be presented graphically over time by opioid type, 
opioid formulation and, where available tablet strength 
(nationally and by jurisdiction). Opioid utilisation data 
will be presented as number of packs and number of 
oral morphine equivalent (OME) grams; the latter will 
be computed using published conversion guidelines.25 
Percentage of total OME/packs will be calculated for 
tapentadol and other opioid formulations to graph the 
underlying rate of sales. Trends over time in tapentadol 
sales will be assessed using negative binomial or gener-
alised estimating equations (to take into account non-in-
dependence), including variables to account for time/
seasonality.
PIC data will be presented as rates of intentional phar-
maceutical opioid exposure poisonings using IMS sales 
data as the denominator; specifically, rates per 100 000 
OME grams and per 1000 packs distributed per month. 
These analyses will be restricted to those cases explicitly 
identified as a pharmaceutical opioid exposure poisoning 
attributable to a type of opioid (eg, tapentadol, oxyco-
done) as per the criteria identified above. Trends over 
time in tapentadol exposures will also be modelled using 
generalised estimating equations.
Various comparators will be used for these analyses, 
including specific pharmaceutical opioid formula-
tions (eg, tramadol, oxycodone), and opioids grouped 
as per WHO guidelines26 into strong prescription opioids 
(buprenorphine, fentanyl, hydromorphone, metha-
done, morphine and oxycodone; all listed as ‘Schedule 
8’ opioids in Australian classification of medicines and 
poisons), other prescription opioids (prescribed codeine, 
dextropropoxyphene and tramadol; ‘Schedule 4’ in 
Australia) and over-the-counter opioids (codeine products 
available at pharmacies without a prescription).
Sentinel data
Cryptomarket and IDRS data will be described using 
descriptive statistics, with the former graphed as number 
of vendors for SRF tapentadol and other pharmaceutical 
opioid formulations by month. Parametric and non-para-
metric tests of significance, as well as measures of effect 
size, will be used to describe differences in rates of extra-
medical use, diversion, attractiveness and overdose for 
tapentadol versus other opioid formulations.
EthICs And dIssEMInAtIon
The authors confirm ethics approval is not required 
for pharmaceutical sales data. Ethics approval has been 
obtained for use of national pharmaceutical opioid 
poisonings reported to Poison Information Centres 
(LNR/16/SCHN/44) and for use of online marketplace 
data and interview data from people who inject drugs 
(HC13081 and HC12086). IDRS participants provided 
informed consent prior to completing the interview.   
We plan to publish our findings mid-2018 in a peer-re-
viewed journal article as per the data sources and outcomes 
listed in table 1 and research questions specified in the 
aims above, and these findings will also be presented at 
conferences. Publications will comply with Strengthening 
the Reporting of Observational Studies in Epidemi-
ology  guidelines.27 Restrictions will apply to the avail-
ability of these data as they are used with approval from 
data custodians for the purposes of this study, but they 
may be available following approval from the researchers, 
custodians of the data and any other involved third party.
dIsCussIon
This postmarketing study forms part of a growing body 
of literature detailing comprehensive and transparent 
monitoring of specific pharmaceutical opioid formu-
lations with key indicators of use, extramedical use 
and harms.28 Concern is growing regarding rates of 
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pharmaceutical opioid extramedical use and harms. 
Consequently, it is important to determine how shifts 
in the pharmaceutical opioid market, including avail-
ability of new formulations, plays out in terms of these 
outcomes. There has been no such undertaking for 
tapentadol globally, despite availability in the US for 
nearly a decade, and indications of a small but growing 
pharmaceutical opioid market share,17 making the 
current study critical.
It should be noted that this study is limited in terms 
of the number of available data sources relative to other 
postmarketing studies.28 However, this is a systems-level 
issue, as tapentadol is not differentiated from other 
pharmaceutical opioids in most healthcare and law 
enforcement data coding systems. There are a number 
of limitations specific to the chosen data sources. IDRS 
reflects a sentinel population at high risk of extra-
medical use, and thus will not reflect general popu-
lation extramedical use, nor will it cover all aspects of 
various outcomes (eg, street price is only one aspect of 
pharmaceutical opioid attractiveness for extramedical 
use). Further, IMS Health sales data does not index 
the number of individuals prescribed opioids, and PIC 
data does not index all individuals with an adverse 
event, the latter often captured in other healthcare 
sources. However, IMS data is estimated to cover over 
94% of all sales nationally,29 making it strong index 
of pharmaceutical opioid exposure in the community. 
Similarly, PIC data has complete coverage nationally 
and captures details related to type of exposure and 
dose critical to understanding risk of adverse expo-
sure. We would also argue that online drug market-
place data and IDRS are necessary and key sentinel 
data sources, being established to identify emerging 
trends in drug use. IDRS participants typically report 
injecting heroin, methamphetamine and/or pharma-
ceutical opioids,24 making valid comparison across 
these substances and across jurisdictions with varying 
levels of heroin and pharmaceutical opioid availability.
In light of these strengths, we think that triangulation 
of these sources will provide a clear picture of tapentadol 
use, extramedical use, attractiveness and associated harms. 
We believe these findings will be critical to understanding 
possible risks in terms of extramedical use and harms if 
tapentadol prescribing increases. More broadly though, 
these findings will help to enhance understanding as to 
the impact changes in the pharmaceutical opioid market 
can have on extramedical use and harms from a policy, 
industry, clinician and research perspective.
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